- Rakovina Therapeutics (RKV) has announced the financial results for its fourth quarter and fiscal year ending December 31, 2021
- For the three and twelve months ending December 31, 2021 the company reported a net loss of $751,353 and $5,521,139, respectively
- R&D operating expenses were $473,799 and $1,502,439 for the three and twelve months ended December 31, 2021, respectively
- Total cash operating expenses for the three and twelve months ended December 31, 2021 were $529,293 and 1,691,905, respectively
- Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies
- Shares of Rakovina Therapeutics Inc. (RKV) are down 6.25 per cent, trading at $0.15 at 12:52 PM ET
Rakovina Therapeutics (RKV) has announced financial results for Q4 and the fiscal year ending December 31, 2021, and provided a corporate update.
On December 31, 2021, the company had positive working capital of approximately $3.0 million.
For the three and twelve months ending December 31, 2021, the company reported a net loss of $751,353 and $5,521,139, respectively.
Research and development operating expenses were $473,799 and $1,502,439 for the three and twelve months ended December 31, 2021, respectively.
General and administrative expenses were $277,907 and $971,891 for the three and twelve months ending December 31, 2021, respectively.
Total cash operating expenses related to research and development and general and administrative expenses for the three and twelve months ended December 31, 2021 were $529,293 and 1,691,905, respectively.
The company embarked on some key projects in the last year of operation. It presented pre-clinical research results with its kt-3000 drug candidates in peer-reviewed scientific meetings, including the JCA-AACR Precision Medicine International Conference (Sept 2021).
On November 16, 2021, Rakovina Therapeutics announced that it had been selected to join a three-year $1,297,000 research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies.
The company commenced operations on March 25, 2021, concurrent with the closing of the qualifying transaction with Vincero Capital Corp. and began trading on the Toronto Venture Exchange under the symbol RKV on April 1, 2021.
Shares of Rakovina Therapeutics Inc. (RKV) are down 6.25 per cent, trading at $0.15 at 12:52 PM ET.
